# A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

> **NCT04936529** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 286 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DIETARY_SUPPLEMENT:** β-glucan
- **DRUG:** GM-CSF
- **BIOLOGICAL:** OPT-821

## Key facts

- **NCT ID:** NCT04936529
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-02
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04936529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04936529, "A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04936529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*